SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-21-244684
Filing Date
2021-08-12
Accepted
2021-08-12 16:12:17
Documents
37
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d210352d10q.htm   iXBRL 10-Q 896216
2 EX-31.1 d210352dex311.htm EX-31.1 10515
3 EX-31.2 d210352dex312.htm EX-31.2 10523
4 EX-32.1 d210352dex321.htm EX-32.1 4490
5 EX-32.2 d210352dex322.htm EX-32.2 4484
  Complete submission text file 0001193125-21-244684.txt   2892057

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ayla-20210630.xsd EX-101.SCH 25136
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ayla-20210630_cal.xml EX-101.CAL 24085
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ayla-20210630_def.xml EX-101.DEF 107788
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ayla-20210630_lab.xml EX-101.LAB 199067
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ayla-20210630_pre.xml EX-101.PRE 149800
11 EXTRACTED XBRL INSTANCE DOCUMENT d210352d10q_htm.xml XML 256191
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39279 | Film No.: 211167677
SIC: 2836 Biological Products, (No Diagnostic Substances)